GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » XOMA Corp (FRA:X0M1) » Definitions » Float Percentage Of Total Shares Outstanding

XOMA (FRA:X0M1) Float Percentage Of Total Shares Outstanding : 68.36% (As of Jun. 10, 2024)


View and export this data going back to 1986. Start your Free Trial

What is XOMA Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, XOMA's float shares is 7.96 Mil. XOMA's total shares outstanding is 11.64 Mil. XOMA's float percentage of total shares outstanding is 68.36%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, XOMA's Insider Ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, XOMA's Institutional Ownership is 24.27%.


XOMA Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

XOMA's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=7.96/11.64
=68.36%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


XOMA (FRA:X0M1) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » XOMA Corp (FRA:X0M1) » Definitions » Float Percentage Of Total Shares Outstanding
Traded in Other Exchanges
Address
2200 Powell Street, Suite 310, Emeryville, CA, USA, 94608
XOMA Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. When XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes.

XOMA (FRA:X0M1) Headlines

No Headlines